ARROWHEAD PHARMACEUTICALS, INC.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent ($81.7m) ($34.4m) ($54.5m) $68.0m ($84.6m) ($140.8m) ($176.1m) ($205.3m) ($599.5m) ($1.6m)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest ($81.7m) ($34.4m) ($54.5m) $68.0m ($84.6m) ($140.8m) ($176.5m) ($209.3m) ($609.7m) $30.1m
Net Income (Loss) Attributable to Noncontrolling Interest ($431k) ($4.0m) ($10.2m) $31.7m
Depreciation, Depletion and Amortization $3.3m $4.7m $4.7m $2.7m $4.2m $6.6m $8.7m $10.7m $16.9m $22.2m
Depreciation $3.3m $4.7m $3.0m $4.4m $5.9m $8.3m $10.4m $12.5m $18.6m $23.9m
Amortization of Intangible Assets $1.7m $1.7m $1.7m $1.7m $1.7m $1.7m $1.7m $1.7m $1.7m $1.7m
Deferred Income Tax Expense (Benefit) $0 $0 $0 $0
Share-based Payment Arrangement, Noncash Expense $11.6m $7.9m $8.5m $12.4m $43.4m $76.7m $120.9m $78.1m $74.0m $63.4m
Payment, Tax Withholding, Share-based Payment Arrangement $634k $439k $55k
Share-based Payment Arrangement, Expense $11.6m $7.9m $67.1m $54.8m
Impairment of Intangible Assets (Excluding Goodwill) $945k
Impairment of Intangible Assets, Finite-lived $0 $0 $0 $0
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) $945k
Income Tax Expense (Benefit) $2k $2k $2k $174k $2k $2k $3.8m $2.8m ($2.8m) $21.4m
Interest Expense Nonoperating $32.4m $89.4m
Other Nonoperating Income (Expense) $57k $1.3m $7k ($583k) $2.1m $765k $1.5m ($1.7m) $5.3m
Changes in operating assets and liabilities:
Additional Financial Items
Increase (Decrease) in Accounts Receivable $75k ($7k) $260k $334k $184k $9.4m ($8.8m) ($1.4m) $0 $57.0m
Increase (Decrease) in Accounts Payable $2.6m ($3.5m) ($1.3m) $4.8m ($821k) $2.6m ($6.6m) $33.0m ($5.5m) $6.3m
Proceeds from Stock Options Exercised $3.6m $8.3m $7.5m $11.3m $5.2m $3.1m $2.4m $4.0m
Gain (Loss) on Investments ($4.4m) $0
General and Administrative Expense $9.9m $6.8m $19.1m $26.6m $52.3m $81.0m $124.4m $92.5m $98.8m $123.9m
Nonoperating Income (Expense) $22k $2.6m $1.5m $7.0m $8.6m $8.2m $5.8m ($1.5m) ($11.4m) ($46.8m)
Operating Expenses $81.9m $68.4m $72.1m $107.6m $181.2m $287.3m $421.7m $445.7m $604.6m $731.1m
Proceeds from Contributed Capital $60.0m $0 $0
Realized Investment Gains (Losses) ($80k) $0
Unrealized Gain (Loss) on Derivatives ($301k) $890k $432k
Net Cash Provided by (Used in) Operating Activities ($64.4m) ($23.9m) ($47.2m) $173.0m ($95.4m) $171.2m ($136.1m) ($153.9m) ($462.9m) $179.6m
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $3.9m $7.9m $1.4m $12.0m $12.0m $23.6m $52.8m $176.7m $141.5m $22.7m
Payments to Acquire Investments $279.0m $240.7m $223.4m $246.1m $720.9m $796.3m
Net Cash Provided by (Used in) Investing Activities $13.4m ($48.6m) ($7.4m) ($47.7m) ($240.8m) ($141.7m) ($5.4m) ($96.2m) ($420.1m) ($129.3m)
Cash flows from financing activities:
Proceeds from Issuance of Common Stock $52.2m $12.4m $56.6m $60.5m $250.5m $0 $0 $0 $429.3m $241.4m
Net Cash Provided by (Used in) Financing Activities $55.1m $12.1m $60.0m $66.4m $257.9m $11.3m $65.2m $253.1m $870.5m $74.0m
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $410k ($88k) ($67k) ($122k) $4.2m ($401k)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $191.7m ($78.2m) $40.9m ($67k) ($122k) $4.2m ($401k)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents ($78.6m) $40.9m $108.0m $110.9m $102.7m $226.5m
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities ($11k) ($188k) $173k $27k $0 $0 $0 $0 $0 $19k
Income Taxes Paid, Net ($2k) ($2k) ($2k) ($302k) $103k ($2k) ($2k) $0 ($3.7m) $814k